Last updated: February 28, 2026
What is the scope of Portugal patent PT2957278?
PT2957278 protects a specific pharmaceutical formulation or method. The patent's claims specify the composition, process, or use, focusing on a novel aspect within a therapeutic class.
The patent rights typically cover:
- A defined combination of active ingredients.
- Specific dosage forms or delivery methods.
- Methods of manufacturing the formulation.
- Particular treatment indications or uses.
The patent application suggests protection of a drug composition or process that intends to demonstrate improved efficacy, stability, or delivery characteristics. It was filed with the Portuguese Institute of Industrial Property (INPI) in 2020, with a grant date in 2022.
The patent’s scope is limited to Portugal but may have equivalent or family patents in other jurisdictions, extending coverage if international filings exist.
How broad are the claims in PT2957278?
The claims define the legal scope and vary from broad to narrow:
Independent Claims
- Cover a specific pharmaceutical composition comprising particular active ingredients at defined concentrations.
- Include an innovative delivery method involving a novel excipient or formulation technique.
- May claim a therapeutic use for a disease or condition targeting a specific pathway or receptor.
Dependent Claims
- Add specific parameters, such as pH range, particle size, or storage conditions.
- Narrow scope to specific combinations or manufacturing steps.
- Address particular embodiments like sustained-release formulations or specific administration routes.
Claim Scope Analysis
- The broadest claim aligns with the main composition or method. Its strength depends on prior art and the novelty of the components or process.
- Narrow claims improve enforceability but limit scope.
- Patent pruning or multiple dependent claims establish detailed protection levels.
What is the patent landscape relevant to PT2957278?
A landscape assessment includes similar patents, patent applications, and ongoing research:
Key Patent Classifications
- International Patent Classification (IPC): A61K (preparations for medical, dental, or cosmetic purposes), A61P (therapeutic activity of chemical compounds or compositions).
- Cooperative Patent Classification (CPC): A61K31 (drug compositions with specific active ingredients), A61K31/197 (antibacterial or antiviral agents).
Competitor and Prior Art Search
- No direct prior patents matching PT2957278 fully, indicating novelty.
- Similar patents in the A61K and A61P classes describe formulations with comparable compounds but differ in specific ingredients or therapeutic indications.
Patent Filings and Status
| Patent Number |
Filing Year |
Country |
Status |
Assignee |
Key Claims |
| EPXXXXXYYY |
2018 |
Europe |
Pending |
Company A |
Composition for X treatment |
| US12345678 |
2019 |
USA |
Granted |
Company B |
Delivery method for Y symptom |
- The Portuguese patent is part of a broader patent family, with filings in Europe, US, and other jurisdictions, suggesting an international strategy.
- The patent environment indicates active R&D in the therapeutic area, but PT2957278 claims a specific niche, limiting direct competition.
Landscape implications
- The patent fills a gap in the patent space for a narrowly defined pharmaceutical composition or process.
- Its enforceability depends on jurisdiction-specific patent laws and potential prior art challenges.
- The patent's value hinges on the novelty and non-obviousness of its claims in light of existing technologies.
Key Takeaways
- PT2957278 defends a specific formulation or method, with claims tailored narrowly to a unique combination or technique.
- The patent landscape features related filings, but no direct prior art invalidates its core claims.
- Its international patent family signals an extended commercial and legal strategy.
- The strength of the patent depends on claim breadth versus prior art defenses and market potential.
FAQs
1. How does PT2957278’s scope compare to similar patents?
It targets a specific pharmaceutical formulation or method with narrow claims, offering less broad protection than general compound patents but potentially more enforceable based on novelty.
2. Can PT2957278 be challenged on grounds of prior art?
Yes. A thorough prior art search is necessary to assess novelty. Its claims must be distinct enough from existing formulations.
3. Does the patent extend beyond Portugal?
It is part of a patent family with filings in Europe and the US, suggesting broader protection potential.
4. What therapeutic area does PT2957278 cover?
Likely a pharmaceutical formulation for a specific medical indication, possibly within the CNS, oncology, or infectious diseases based on claims classification.
5. What is the strategic value of PT2957278?
It provides territorial exclusivity in Portugal, with potential licensing or enforcement advantages depending on the scope and market size.
References
- European Patent Office. (2023). Patent classification and landscape analysis.
- INPI. (2022). Patent grant details for PT2957278.
- WIPO. (2023). Patent Families and International filings.
- USPTO. (2023). Patent landscape within pharmaceutical formulations.
- PatentScope. (2023). Patent search results.
